An observational study in GLP-1 Receptor Agonist Treatment, sponsored by University of Virginia. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Virginia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 344 studies in Pneumonia with a site in United States — 41 open to participants now, 53 under way, 8 of them phase 3. Pneumonia · United States.
Among the 344 studies in Pneumonia with a site in United States, this one is the 8th largest by enrollment of the 78 observational ones that give a count, is one of 8 that started in 2025, is one of 78 observational ones, and was the 344th registered.
1,566 studies on the registry are indexed under Pneumonia; 266 are open to participants now.
Browse Pneumonia studies →41 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
MiNK Therapeutics · Sites in United States, Ukraine
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 47 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
344 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 81 · Phase 3 55 · Phase 4 32
First in 1994; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25,505 is above the median of 254 across 536 observational studies indexed under Pneumonia.
Median enrollment 91 across the 263 interventional studies, 325 across the 78 observational. Of the 257 that completed or were terminated, 101 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 344 have an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 676 studies on the registry; 138 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 3 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
22 of the studies in Pneumonia with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365826Phase 3Vaxcyte, Inc.A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | 2027-03 |
| NCT07425392Phase 3Vaxcyte, Inc.Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | 2027-03 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 22 to your calendar (.ics) → With an account.
Among the 344 studies in Pneumonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among adult elective surgical patients is increasing. The exact prevalence is unclear, and the possible association with pulmonary aspiration is a major concern. This study was designed to quantify the prevalence of GLP-1 RA use and the incidence of perioperative aspiration among other 30-day pulmonary complications in adult elective surgical patients at a single institution in 2025.
All elective surgeries for adult patients (≥ 18 years of age) performed at University of Virginia operative sites were queried, inclusive of the main operating room and three outpatient surgical centers (on-site multispecialty, off-site multispecialty, and off-site orthopaedics).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult elective surgical patients
Drug: GLP-1 Receptor Agonists
Adult elective surgical patients with body mass index ≥ 25 kg/m2 who underwent non-brain, non-cardiac surgery with overnight stay after general anesthesia with orotracheal intubation and a surgical duration of at least two hours
Drug: GLP-1 Receptor Agonists
Outpatient treatment with any GLP-1 RA, regardless of dosing interval (daily versus weekly). The following medications were considered medications of interest: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, tirzepatide, albiglutide, efpeglenatide
Control group; GLP-1 RA non-users
Perioperative aspiration
Time frame: Index surgical encounter
Aspiration
Time frame: 30 days
Pneumonia
Time frame: 30 days
Aspiration or pneumonia
Time frame: 30 days
Aspiration, pneumonia, or other respiratory complication
Time frame: 30 days
Mortality
Time frame: 30 days
Mortality
Time frame: 90 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Nov 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.